XLONANCR
Market cap212mUSD
Jan 07, Last price
244.25GBP
1D
0.41%
1Q
3.36%
Jan 2017
-18.00%
IPO
327.83%
Name
Animalcare Group PLC
Chart & Performance
P/E
14,051.28
P/S
226.59
EPS
0.02
Div Yield, %
0.02%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
0.51%
Revenues
74m
+3.82%
Net income
1m
-38.98%
CFO
10m
+9.04%
Dividend
Oct 17, 20242 GBP/sh
Earnings
Apr 07, 2025
Profile
Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in the wholesale and marketing of veterinary pharmaceuticals. The company serves customers in Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, other European countries, Asia, the Middle East, Africa, and internationally. Animalcare Group plc was incorporated in 1972 and is based in York, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | ||||||||||
Revenues | 74,351 3.82% | 71,616 -3.25% | ||||||||
Cost of revenue | 54,353 | 61,867 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 19,998 | 9,749 | ||||||||
NOPBT Margin | 26.90% | 13.61% | ||||||||
Operating Taxes | 2,324 | 577 | ||||||||
Tax Rate | 11.62% | 5.92% | ||||||||
NOPAT | 17,674 | 9,172 | ||||||||
Net income | 1,199 -38.98% | 1,965 -2,651.95% | ||||||||
Dividends | (2,644) | (2,644) | ||||||||
Dividend yield | 2.56% | 1.91% | ||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 914 | 852 | ||||||||
Long-term debt | 7,905 | 13,596 | ||||||||
Deferred revenue | 293 | 372 | ||||||||
Other long-term liabilities | 1,209 | 1,251 | ||||||||
Net debt | 2,988 | 7,038 | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | 10,281 | 9,429 | ||||||||
CAPEX | (52) | (2,947) | ||||||||
Cash from investing activities | (2,859) | (3,119) | ||||||||
Cash from financing activities | (8,950) | (5,696) | ||||||||
FCF | 16,764 | 6,682 | ||||||||
| Balance | ||||||||||
Cash | 4,642 | 6,035 | ||||||||
Long term investments | 1,189 | 1,375 | ||||||||
Excess cash | 2,113 | 3,829 | ||||||||
Stockholders' equity | 1,859 | 2,950 | ||||||||
Invested Capital | 83,414 | 88,473 | ||||||||
ROIC | 20.56% | 10.35% | ||||||||
ROCE | 22.40% | 10.13% | ||||||||
| EV | ||||||||||
Common stock shares outstanding | 60,654 | 60,804 | ||||||||
Price | 1.70 -25.27% | 2.28 -34.06% | ||||||||
Market cap | 103,112 -25.46% | 138,330 -33.28% | ||||||||
EV | 106,100 | 145,368 | ||||||||
EBITDA | 27,703 | 17,552 | ||||||||
EV/EBITDA | 3.83 | 8.28 | ||||||||
Interest | 859 | 444 | ||||||||
Interest/NOPBT | 4.30% | 4.55% | ||||||||